Safety and efficacy of antibiotics in the prophylaxis of group B Streptococcus in pregnant women
Article Sidebar
Main Article Content
Abstract
Objective: Critically analyze the safety and efficacy of antibiotics in the prophylaxis of Group B Streptococcus (GBS) in pregnant women. Methods: This integrative review, based on PubMed Central (PMC), aims to critically evaluate the safety and efficacy of antibiotics in GBS prophylaxis in pregnant women. The research used the descriptors 'Pregnancy', 'Antibiotic Prophylaxis', 'Group B Streptococcus'. Out of 154 identified articles, only 14 were selected for thorough analysis based on inclusion and exclusion criteria. Results: The results highlight penicillin as the drug of choice but underscore the growing concern about antimicrobial resistance, justifying the use of cefazolin in specific situations. The analysis revealed that penicillin use does not show a significant association with the development of atopic conditions. The results emphasize the effectiveness of intrapartum antibiotic prophylaxis in preventing bacterial infections caused by GBS in newborns. However, there is a need for additional research to assess therapeutic alternatives in cases of antimicrobial resistance and penicillin allergies. Final considerations: Antibiotic prophylaxis is crucial in GBS-colonized pregnant women, requiring additional studies to guide best practices.
Article Details
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
References
2. AMERICAN COLLEGE OF OBSTETRICIANS AND GYNECOLOGISTS et al. ACOG Committee Opinion: number 797. Prevention of Group B Streptococcal Early-Onset Disease in Newborns. Obstetrics and gynecology, 2020, 135(2):e51-e72.
3. ANTONELLO VS, et al. Alternative antimicrobials for prophylaxis of the Group B Streptococcus maternal-fetal disease. The Journal of Infection in Developing Countries, 2020, 14(6): 664-668 .
4. CHEN JC, et al. Early‐onset Group B Streptococcal disease in a risk factor‐based prevention setting: A 15‐year population‐based study. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2019; 59(3): 422-429.
5. CHEN X, et al. The risk factors for Group B Streptococcus colonization during pregnancy and influences of intrapartum antibiotic prophylaxis on maternal and neonatal outcomes. BMC Pregnancy and Childbirth, 2023, 23(1): 1-9.
6. DAVIES HG, et al. Group B Streptococcus: trials and tribulations. The Pediatric Infectious Disease Journal, 2019; 38(6S Suppl 1): S72-S76.
7. DAKIN A, et al. Assessing standards for prevention of early onset group B streptococcal (GBS) disease in Ireland. Ir J Med Sci, 2022; 191(2): 785-791.
8. DOENHARDT M, et al. Neonatal and young infant sepsis by Group B Streptococci and Escherichia coli: a single-center retrospective analysis in Germany-GBS screening implementation gaps and reduction in antibiotic resistance. Eur J Pediatr, 2020; 179 (11): 1769-1777.
9. DHUDASIA MB, et al. Intrapartum Group B Streptococcal Prophylaxis and Childhood Allergic Disorders. Pediatrics, 2021; 147(5): e2020012187.
10. HAMDAN L, et al. Epidemiological Trends of Racial Differences in Early- and Late-onset Group B Streptococcus Disease in Tennessee. Clin Infect Dis., 2021; 73(11): e3634-e3640.
11. JISUVEI SC, et al. Prevalence, antimicrobial susceptibility patterns, serotypes and risk factors for group B Streptococcus rectovaginal isolates among pregnant women at Kenyatta National Hospital, Kenya; a cross-sectional study. BMC Infect Dis, 2020; 20(1): 302.
12. KIRVEN J, et al. Outcomes in reported penicillin allergic mothers and neonates requiring Group B Streptococcal prophylaxis: a retrospective observational cohort study. BMC Pediatr, 2021; 21(1): 327.
13. LE DK, et al. Uncertainties in screening and prevention of group B Streptococcus disease. Clinical Infectious Diseases, 2019; 69(4):720-725.
14. LEE CC, et al. Clinical and Microbiological Characteristics of Group B Streptococcus from Pregnant Women and Diseased Infants in Intrapartum Antibiotic Prophylaxis Era in Taiwan. Sci Rep., 2019; 9(1): 13525.
15. RAABE VN e SHANE AL. Group B Streptococcus (Streptococcus agalactiae). Microbiol Spectr, 2019; 7(2):10.
16. SAID M, et al. Antimicrobial susceptibility and serotype distribution of Streptococcus agalactiae rectovaginal colonising isolates from pregnant women at a tertiary hospital in Pretoria, South Africa: An observational descriptive study. S Afr Med J, 2020; 110(9): 869-871.
17. SHIRODA M, et al. The impact of Lactobacillus on group B Streptococcal interactions with cells of the extraplacental. Microb Pathog, 2020, 148: 10446.
18. SNIDER JB, et al. Antibiotic choice for Group B Streptococcus prophylaxis in mothers with reported penicillin allergy and associated newborn outcomes. BMC Pregnancy and Childbirth, 2023; 23(10): 400.
19. STEER PJ, et al. Group B Streptococcal disease in the mother and newborn-A review. Eur J Obstet Gynecol Reprod Bio, 2020; 252: 526-533.
20. SUBRAMANIAM A, et al. Prevalence of group B Streptococcus anogenital colonization and feasibility of an intrapartum screening and antibiotic prophylaxis protocol in Cameroon, Africa. Int J Gynaecol Obstet., 2019;146(2):238-243.
21. ZHU Y e LIN XZ. Updates in prevention policies of early-onset group B Streptococcal infection in newborns. Pediatr Neonatol, 2021; 62(5):465-475.